Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):6-11. doi: 10.5588/ijtld.16.0110.

Abstract

Background: Estimates of the multidrug-resistant tuberculosis (MDR-TB) burden are based on incomplete, infrequently updated data among a limited pool of notified or incident pulmonary TB cases.

Methods: Using World Health Organization data reported by 217 countries/territories in 2014, we calculated the MDR-TB burden among prevalent TB cases and compared these with estimates among incident and notified TB patients. We also compared treatment coverage across estimates.

Results: Among prevalent TB patients worldwide in 2014, we estimate that 555 545 (95% credible bounds 499 340-617 391) MDR-TB cases occurred. This is 85% more than the 300 000 estimated among notified cases, and 16% more than the 480 000 among incident cases. Only 20% of MDR-TB cases among prevalent-compared to 37% of MDR-TB among notified-TB patients had access to MDR-TB treatment. Applying prior estimates, only 10% of MDR-TB cases will have successful outcomes.

Conclusion: Estimates based on likely-to-be-diagnosed cases of MDR-TB overlook a significant proportion of morbidity, mortality, and transmission that occur in undiagnosed, untreated, prevalent TB patients. Even though it may still likely underestimate the true disease burden, MDR-TB among patients with prevalent TB represents a closer approximation of disease burden than currently reported indicators. Progress toward elimination or control depends on policies guided by a more complete representation of the disease burden.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Cohort Studies
  • Cost of Illness
  • Global Health*
  • Humans
  • Prevalence
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology*
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology*

Substances

  • Antitubercular Agents